Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial

Divya Nair, MD, Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Salli A Fennessey, Kathleen T Finn, ANP, Martha Skinner, MD, Jerome B. Zeldis, MD, PhD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 4084.

https://doi.org/10.1182/blood.V120.21.4084.4084

Published: 2012

Journal Articles

High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis

Vaishali Sanchorawala, MD, Karen Quillen, MD, MPH, Kathleen T Finn, ANP, Nancy T Andrea, MD, J. Mark Sloan, MD, Laura Dember, MD, Adam Segal, MD, Gheorghe Doros, PhD, Martha Skinner, MD, David Seldin, MD

Blood (2010) 116 (21): 3553.

https://doi.org/10.1182/blood.V116.21.3553.3553

Published: 2010

Journal Articles

Macroglossia – Not Always AL Amyloidosis

Andrew J Cowan, MD, Martha Skinner, MD, J. Mark Sloan, MD, John L Berk, MD, Carl J O'Hara, MD, David C Seldin, MD, PhD, Vaishali Sanchorawala, MD

Blood (2010) 116 (21): 5007.

https://doi.org/10.1182/blood.V116.21.5007.5007

Published: 2010

Journal Articles

Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

M. Teresa Cibeira, MD, PhD, Vaishali Sanchorawala, MD, David C Seldin, MD, PhD, Karen Quillen, MD, MPH, Nancy Andrea, MD, J. Mark Sloan, MD, Kathleen T Finn, ANP, John L Berk, MD, Gheorghe Doros, PhD, Joan Blade, Martha Skinner, MD

Blood (2010) 116 (21): 2394.

https://doi.org/10.1182/blood.V116.21.2394.2394

Published: 2010

Journal Articles

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis.

Saulius Girnius, MD, Frank Tsai, MD, David C. Seldin, MD, PhD, Karen Quillen, MD, Lisa Yanarella, NP, Kathleen T. Finn, NP, Nancy T. Andrea, MD, John Mark Sloan, MD, Martha Skinner, MD, Vaishali Sanchorawala, MD

Blood (2009) 114 (22): 4352.

https://doi.org/10.1182/blood.V114.22.4352.4352

Published: 2009

Journal Articles

Localized AL Amyloidosis of the Breast: A Case Series.

Marjory Charlot, MD, David C. Seldin, MD, PhD, Carl O'Hara, MD, Martha Skinner, MD, Vaishali Sanchorawala, MD

Blood (2009) 114 (22): 4906.

https://doi.org/10.1182/blood.V114.22.4906.4906

Published: 2009

Journal Articles

Hepatic Response after High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Associated Liver Disease.

Saulius Girnius, MD, David C. Seldin, MD, PhD, Martha Skinner, MD, Kathleen T. Finn, NP, Vaishali Sanchorawala, MD

Blood (2007) 110 (11): 2873.

https://doi.org/10.1182/blood.V110.11.2873.2873

Published: 2007

Journal Articles

Durable Responses to Lenalidomide (Revlimid®) in Patients with AL Amyloidosis: Follow Up of a Phase II Trial.

David C. Seldin, MD, PhD, Michael Rosenzweig, MD, Kathleen T. Finn, RN, NP, Salli Fennessey, Anthony Shelton, Jerome B. Zeldis, MD, Martha Skinner, MD, Vaishali Sanchorawala, MD

Blood (2007) 110 (11): 192.

https://doi.org/10.1182/blood.V110.11.192.192

Published: 2007

Journal Articles

Cardiac Transplant Followed by High-Dose Melphalan and Autologous Stem Cell Transplantation (ASCT) for Patients with AL Amyloidosis and Severe Heart Failure.

Bimalangshu R. Dey, MD, PhD, Thomas R. Spitzer, MD, Thomas E. MacGillivray, MD, Stephen S. Chung, MD, G.W. Dec, MD, David C. Seldin, MD, Steven L. McAfee, MD, Karen Ballen, MD, Eyal Attar, MD, Martha Skinner, MD, Joren C. Madsen, MD, DPhil, Marc J. Semigran, MD

Blood (2007) 110 (11): 732.

https://doi.org/10.1182/blood.V110.11.732.732

Published: 2007

Journal Articles

Relapse Rate and Long-Term Survival of AL Amyloidosis Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).

David C. Seldin, MD, PhD, Martha Skinner, MD, Betul Oran, MD, Karen Quillen, MD, Kathleen T. Finn, RN, NP, Vaishali Sanchorawala, MD

Blood (2006) 108 (11): 3094.

https://doi.org/10.1182/blood.V108.11.3094.3094

Published: 2006

Journal Articles

Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation: Final Analysis of a Prospective Trial.

Vaishali Sanchorawala, MD, Daniel G. Wright, MD, Karen Quillen, MD, Laura M. Dember, MD, John L. Berk, MD, Kathleen T. Finn, RN, Martha Skinner, MD, David C. Seldin, MD, PhD

Blood (2006) 108 (11): 612.

https://doi.org/10.1182/blood.V108.11.612.612

Published: 2006

Journal Articles

Expression of Human Amyloidogenic Immunoglobulin Light Chains in Mice Leads to Organ Toxicity.

Jennifer E. Ward, PhD, Daniel Brenner, PhD, Lei Cui, PhD, Ronglih Liao, PhD, Lawreen H. Connors, PhD, Pam Soo Hoo, BS, Jeremy Eberhard, BA, Thomas Christensen, PhD, Carl O’Hara, MD, Martha Skinner, MD, David C. Seldin, MD/PhD

Blood (2005) 106 (11): 3412.

https://doi.org/10.1182/blood.V106.11.3412.3412

Published: 2005

Journal Articles

High-Dose Melphalan and Autologous Stem Cell Transplantation in Unusual Non-Amyloid Light Chain Deposition Disorders.

Karin I. Weichman, MD, David C. Seldin, MD, PhD, Karen Quillen, MD, Michael Rosenzweig, MD, Laura M. Dember, MD, Martha Skinner, MD, Daniel G. Wright, MD, Vaishali Sanchorawala, MD

Blood (2005) 106 (11): 5476.

https://doi.org/10.1182/blood.V106.11.5476.5476

Published: 2005

Journal Articles

Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis.

Cynthia A. Kos, MA, Jennifer E. Ward, Karim Malek, MD, Vaishali Sanchorawala, MD, Daniel G. Wright, MD, Carl O’Hara, MD, Lawreen Connors, Ph.D, Martha Skinner, MD, David C. Seldin, MD

Blood (2005) 106 (11): 4078.

https://doi.org/10.1182/blood.V106.11.4078.4078

Published: 2005

Journal Articles

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Predict Treatment Outcomes.

Vaishali Sanchorawala, MD, Daniel G. Wright, MD, Karen Quillen, MD, Catherine Fisher, RN, Martha Skinner, MD, David C. Sedlin, MD, PhD

Blood (2005) 106 (11): 1160.

https://doi.org/10.1182/blood.V106.11.1160.1160

Published: 2005

Journal Articles

Successful Treatment of AL Amyloidosis Patients over Age 65 with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).

David Cary Seldin, MD, PhD, Jennifer J. Anderson, PhD, Martha Skinner, MD, Karim Malek, MD, Daniel G. Wright, MD, Karen Quillen, MD, Vaishali Sanchorawala, MD

Blood (2004) 104 (11): 923.

https://doi.org/10.1182/blood.V104.11.923.923

Published: 2004

Journal Articles

Serum Free Light Chain Responses after High-Dose Intravenous Melphalan and Autologous Stem Cell Transplantation for AL (Primary) Amyloidosis.

Vaishali Sanchorawala, MD, Daniel G. Wright, MD, Barbarajean Magnani, MD, PhD, Martha Skinner, MD, David C. Seldin, MD, PhD

Blood (2004) 104 (11): 942.

https://doi.org/10.1182/blood.V104.11.942.942

Published: 2004

Journal Articles

Pulsed Low Dose Intravenous Melphalan in Patients with AL Amyloidosis, Ineligible for Aggressive Treatment with High-Dose Melphalan and Stem Cell Transplantation.

Vaishali Sanchorawala, MD, David C. Seldin, MD, PhD, Daniel G. Wright, MD, Martha Skinner, MD, Kathleen T. Finn, RN, NP, Rodney H. Falk, MD

Blood (2004) 104 (11): 2393.

https://doi.org/10.1182/blood.V104.11.2393.2393

Published: 2004

Journal Articles

Feasibility of Second Autologous Peripheral Blood Stem Cell (PBSC) Collection Followed by a Second Cycle of High Dose Melphalan (HDM) in Patients Relapsing after an Initial Course of HDM for the Treatment of AL Amyloidosis.

Karen Quillen, MD, Daniel G. Wright, MD, David C. Seldin, MD PhD, Martha Skinner, MD, Karim Malek, MD, Kathleen T. Finn, RN, Vaishali Sanchorawala, MD

Blood (2004) 104 (11): 5226.

https://doi.org/10.1182/blood.V104.11.5226.5226

Published: 2004

NARROW

Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial

High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis

Macroglossia – Not Always AL Amyloidosis

Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis.

Localized AL Amyloidosis of the Breast: A Case Series.

Hepatic Response after High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Associated Liver Disease.

Durable Responses to Lenalidomide (Revlimid®) in Patients with AL Amyloidosis: Follow Up of a Phase II Trial.

Cardiac Transplant Followed by High-Dose Melphalan and Autologous Stem Cell Transplantation (ASCT) for Patients with AL Amyloidosis and Severe Heart Failure.

Relapse Rate and Long-Term Survival of AL Amyloidosis Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).

Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation: Final Analysis of a Prospective Trial.

Expression of Human Amyloidogenic Immunoglobulin Light Chains in Mice Leads to Organ Toxicity.

High-Dose Melphalan and Autologous Stem Cell Transplantation in Unusual Non-Amyloid Light Chain Deposition Disorders.

Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis.

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Predict Treatment Outcomes.

Successful Treatment of AL Amyloidosis Patients over Age 65 with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).

Serum Free Light Chain Responses after High-Dose Intravenous Melphalan and Autologous Stem Cell Transplantation for AL (Primary) Amyloidosis.

Pulsed Low Dose Intravenous Melphalan in Patients with AL Amyloidosis, Ineligible for Aggressive Treatment with High-Dose Melphalan and Stem Cell Transplantation.

Feasibility of Second Autologous Peripheral Blood Stem Cell (PBSC) Collection Followed by a Second Cycle of High Dose Melphalan (HDM) in Patients Relapsing after an Initial Course of HDM for the Treatment of AL Amyloidosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only